JP6231995B2 - 眼の疾患の合併症を低減するための薬学的組成物 - Google Patents

眼の疾患の合併症を低減するための薬学的組成物 Download PDF

Info

Publication number
JP6231995B2
JP6231995B2 JP2014556741A JP2014556741A JP6231995B2 JP 6231995 B2 JP6231995 B2 JP 6231995B2 JP 2014556741 A JP2014556741 A JP 2014556741A JP 2014556741 A JP2014556741 A JP 2014556741A JP 6231995 B2 JP6231995 B2 JP 6231995B2
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
steroid
group
lipid cake
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2014556741A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015506983A5 (enExample
JP2015506983A (ja
Inventor
クールン ホン,
クールン ホン,
ルーク エス.エス. グオ,
ルーク エス.エス. グオ,
ユン−ロン ツェン,
ユン−ロン ツェン,
シェウ−ファン シー,
シェウ−ファン シー,
ポ−チュン チャン,
ポ−チュン チャン,
チー−チャン ツァイ,
チー−チャン ツァイ,
ホン−フイ リン,
ホン−フイ リン,
Original Assignee
タイワン リポソーム カンパニー リミテッド
タイワン リポソーム カンパニー リミテッド
ティーエルシー バイオファーマシューティカルズ、インク.
ティーエルシー バイオファーマシューティカルズ、インク.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by タイワン リポソーム カンパニー リミテッド, タイワン リポソーム カンパニー リミテッド, ティーエルシー バイオファーマシューティカルズ、インク., ティーエルシー バイオファーマシューティカルズ、インク. filed Critical タイワン リポソーム カンパニー リミテッド
Publication of JP2015506983A publication Critical patent/JP2015506983A/ja
Publication of JP2015506983A5 publication Critical patent/JP2015506983A5/ja
Application granted granted Critical
Publication of JP6231995B2 publication Critical patent/JP6231995B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2014556741A 2012-02-10 2013-02-08 眼の疾患の合併症を低減するための薬学的組成物 Active JP6231995B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261597189P 2012-02-10 2012-02-10
US61/597,189 2012-02-10
PCT/US2013/025390 WO2013119988A1 (en) 2012-02-10 2013-02-08 Pharmaceutical compositions to reduce complications of ocular steroid

Publications (3)

Publication Number Publication Date
JP2015506983A JP2015506983A (ja) 2015-03-05
JP2015506983A5 JP2015506983A5 (enExample) 2016-03-24
JP6231995B2 true JP6231995B2 (ja) 2017-11-15

Family

ID=48948063

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014556741A Active JP6231995B2 (ja) 2012-02-10 2013-02-08 眼の疾患の合併症を低減するための薬学的組成物

Country Status (18)

Country Link
US (2) US10058616B2 (enExample)
EP (1) EP2797601B1 (enExample)
JP (1) JP6231995B2 (enExample)
KR (1) KR102060210B1 (enExample)
CN (2) CN104125830B (enExample)
AU (1) AU2013216861B2 (enExample)
BR (1) BR112014018393B1 (enExample)
CA (1) CA2862055C (enExample)
CY (1) CY1120323T1 (enExample)
DK (1) DK2797601T3 (enExample)
ES (1) ES2673330T3 (enExample)
IN (1) IN2014MN01571A (enExample)
NZ (1) NZ628124A (enExample)
PT (1) PT2797601T (enExample)
RU (1) RU2660585C2 (enExample)
TR (1) TR201808592T4 (enExample)
TW (1) TWI620578B (enExample)
WO (1) WO2013119988A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201809136UA (en) * 2016-04-19 2018-11-29 Univ Nanyang Tech Subconjuctival depot forming formulations for ocular drug delivery
US11766421B2 (en) 2017-09-25 2023-09-26 Surface Ophthalmics, Inc. Ophthalmic pharmaceutical compositions and methods for treating ocular surface disease
CA3080166A1 (en) 2017-11-21 2019-05-31 Axerovision, Inc. Compositions and methods of use for treating aberrant inflammation in peri-ocular secretory glands or at the ocular surface
EP3820479B1 (en) 2018-07-09 2026-03-11 Taiwan Liposome Co., Ltd. Methods to reduce complications of intra-articular steroid
IL281513B1 (en) 2018-09-16 2026-07-01 Tlc Biopharmaceuticals Inc Preparations for the treatment of joint pain
JP2022516099A (ja) 2018-12-27 2022-02-24 サーフィス オフサルミクス,インコーポレイテッド 眼科用医薬組成物及び癌表面疾患の処置方法
RU2716429C1 (ru) * 2019-05-29 2020-03-11 федеральное государственное автономное учреждение "Национальный медицинский исследовательский центр "Межотраслевой научно-технический комплекс "Микрохирургия глаза" имени академика С.Н. Федорова" Министерства здравоохранения Российской Федерации Способ лечения рецидивирующей эрозии роговицы различного генеза
CN111415822A (zh) * 2020-03-05 2020-07-14 沈阳农业大学 一种洋葱碳/二氧化锰阵列电极及其制备方法和应用
US20240156839A1 (en) * 2021-03-05 2024-05-16 Taiwan Liposome Company, Ltd. Pharmaceutical compositions with reduced side effect and methods of using the same
CN117979951A (zh) 2021-05-10 2024-05-03 瑟菲斯眼科股份有限公司 一种用于缓解眼部疼痛的硫酸软骨素的用途
US12440510B2 (en) 2021-05-10 2025-10-14 Surface Ophthalmics, Inc. Use of chondroitin sulfate for relieving ocular pain

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4804539A (en) 1986-07-28 1989-02-14 Liposome Technology, Inc. Ophthalmic liposomes
SE9100342D0 (sv) 1991-02-04 1991-02-04 Astra Ab Novel steroid esters
IL103907A0 (en) * 1992-11-27 1993-04-04 Pharmos Corp Ophthalmic compositions
AU2003298738A1 (en) * 2002-11-26 2004-06-18 Su-Ming Chiang Liposomal formulations
EP1590006B1 (en) 2003-02-04 2010-09-08 Bracco Suisse SA Ultrasound contrast agents and process for the preparation thereof
KR100862930B1 (ko) * 2004-06-23 2008-10-13 시리온 테라퓨틱스, 인크. 레티닐 유도체를 사용하여 안 증상을 치료하기 위한 방법및 조성물
US7767217B2 (en) * 2006-03-14 2010-08-03 Foresight Biotherapeutics Ophthalmic compositions comprising povidone-iodine
EP1864668B1 (en) * 2006-06-01 2012-11-21 Novagali Pharma S.A. Use of prodrugs for ocular intravitreous administration
AU2007260872A1 (en) * 2006-06-22 2007-12-27 Sirion Therapeutics, Inc Methods and compositions for treating ophthalmic conditions via modulation of megalin activity
US20080118500A1 (en) * 2006-11-16 2008-05-22 Taiwan Liposome Company Sustained releasing composition via local injection for treating eye diseases
WO2009107753A1 (ja) * 2008-02-29 2009-09-03 財団法人 名古屋産業科学研究所 後眼部到達用リポソーム及び後眼部疾患用医薬組成物
CN101502485A (zh) * 2009-03-20 2009-08-12 中国药科大学 地塞米松眼用纳米立方液晶制剂及其制备方法
CN101926769A (zh) * 2009-06-24 2010-12-29 天津金耀集团有限公司 地塞米松磷酸钠脂质体注射液
US8956600B2 (en) * 2009-08-10 2015-02-17 Taiwan Liposome Co. Ltd. Ophthalmic drug delivery system containing phospholipid and cholesterol
SG184127A1 (en) * 2010-03-19 2012-10-30 Massachusetts Inst Technology Lipid vesicle compositions and methods of use
US20130217657A1 (en) * 2011-12-21 2013-08-22 Insite Vision Incorporated Combination anti-inflammatory ophthalmic compositions

Also Published As

Publication number Publication date
US20180193461A1 (en) 2018-07-12
NZ628124A (en) 2016-06-24
ES2673330T3 (es) 2018-06-21
BR112014018393A2 (enExample) 2017-06-20
EP2797601A1 (en) 2014-11-05
JP2015506983A (ja) 2015-03-05
WO2013119988A1 (en) 2013-08-15
PT2797601T (pt) 2018-06-27
CN104125830B (zh) 2018-01-16
CN104125830A (zh) 2014-10-29
BR112014018393A8 (pt) 2017-07-11
CN107260679B (zh) 2020-07-31
RU2660585C2 (ru) 2018-07-06
KR20150008844A (ko) 2015-01-23
DK2797601T3 (en) 2018-06-14
RU2014132553A (ru) 2016-02-27
TR201808592T4 (tr) 2018-07-23
EP2797601B1 (en) 2018-03-21
AU2013216861B2 (en) 2017-05-18
KR102060210B1 (ko) 2019-12-27
TWI620578B (zh) 2018-04-11
CY1120323T1 (el) 2019-07-10
CA2862055A1 (en) 2013-08-15
US10350294B2 (en) 2019-07-16
TW201338806A (zh) 2013-10-01
CA2862055C (en) 2020-03-10
BR112014018393B1 (pt) 2020-09-15
IN2014MN01571A (enExample) 2015-05-15
US10058616B2 (en) 2018-08-28
US20150011520A1 (en) 2015-01-08
CN107260679A (zh) 2017-10-20
AU2013216861A1 (en) 2014-08-07
HK1201723A1 (en) 2015-09-11
EP2797601A4 (en) 2015-06-03

Similar Documents

Publication Publication Date Title
US10350294B2 (en) Pharmaceutical compositions to reduce complications of ocular steroid
TWI857961B (zh) 減少關節內類固醇的併發症之方法
ES3058285T3 (en) Pharmaceutical compositions with reduced side effect and methods of using the same
HK1242192B (en) Pharmaceutical compositions to reduce complications of ocular steroid
WO2021185343A1 (zh) 格列本脲脂质体组合物及其制备方法
HK1242192A1 (en) Pharmaceutical compositions to reduce complications of ocular steroid
US12514820B2 (en) Pharmaceutical composition of intra-articular corticosteroid for pain control
HK1201723B (en) Pharmaceutical compositions to reduce complications of ocular steroid
RU2806023C2 (ru) Способы уменьшения осложнений от внутрисуставного стероида
TW202519194A (zh) 用於疼痛控制之關節內皮質類固醇的微脂體組成物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160202

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160202

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20160909

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20161014

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20161125

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20161206

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170227

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170523

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170606

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20170523

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170906

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20170926

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20171020

R150 Certificate of patent or registration of utility model

Ref document number: 6231995

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250